Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 4.51 and last traded at GBX 4.92, with a volume of 558574 shares. The stock had previously closed at GBX 5.
Allergy Therapeutics Stock Performance
The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The company’s 50-day moving average is GBX 5.80 and its 200 day moving average is GBX 8.40. The company has a market cap of £316.63 million, a price-to-earnings ratio of -5.15, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
- Chewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for Investors
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
